{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:29:25Z","timestamp":1790173765365,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12094-019-02207-7","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T12:33:09Z","timestamp":1569414789000},"page":"900-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Network indirect comparison of 3 BRAF\u2009+\u2009MEK inhibitors for the treatment of advanced BRAF mutated melanoma"],"prefix":"10.1007","volume":"22","author":[{"given":"F.","family":"Consoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bersanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Perego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Merelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"F.","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"2207_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of research involving human participants and\/or animals with advanced metastatic melanoma: the impact of the novel therapies: update 2017. Eur J Cancer. 2017;83:247\u201357. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2017.06.028\n\n.","journal-title":"Eur J Cancer"},{"issue":"24","key":"2207_CR2","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR. Classifying braf alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene. 2018;37(24):3183\u201399. \nhttps:\/\/doi.org\/10.1038\/s41388-018-0171-x\n\n.","journal-title":"Oncogene"},{"issue":"1","key":"2207_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/modpathol.2017.104","volume":"31","author":"L Cheng","year":"2018","unstructured":"Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24\u201338. \nhttps:\/\/doi.org\/10.1038\/modpathol.2017.104\n\n.","journal-title":"Mod Pathol"},{"issue":"14","key":"2207_CR4","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","volume":"47","author":"AM Eggermont","year":"2011","unstructured":"Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer. 2011;47(14):2150\u20137. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2011.06.052\n\n.","journal-title":"Eur J Cancer"},{"issue":"26","key":"2207_CR5","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1103782\n\n.","journal-title":"N Engl J Med"},{"issue":"9839","key":"2207_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open\u2013label, phase 3 randomized controlled trial. Lancet. 2012;380(9839):358\u201365. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X\n\n.","journal-title":"Lancet"},{"issue":"4","key":"2207_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436\u201344. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(14)70051-8\n\n.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2207_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(14)70012-9\n\n.","journal-title":"Lancet Oncol"},{"issue":"20","key":"2207_CR9","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877\u201388. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1406037\n\n.","journal-title":"N Engl J Med"},{"issue":"3","key":"2207_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1105358","volume":"366","author":"F Su","year":"2012","unstructured":"Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. Ras mutations in cutaneous squamous-cell carcinoma in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207\u201315. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1105358\n\n.","journal-title":"N Engl J Med"},{"issue":"1","key":"2207_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, et al. Improved Overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u20139. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1412690\n\n.","journal-title":"N Engl J Med"},{"issue":"9","key":"2207_CR12","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dr\u00e9no B, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248\u201360. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(16)30122-X\n\n.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2207_CR13","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315\u201327. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(18)30497-2\n\n.","journal-title":"Lancet Oncol"},{"issue":"5","key":"2207_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603\u201315. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6\n\n.","journal-title":"Lancet Oncol"},{"key":"2207_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","volume":"82","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, et al. Three-year pooled analysis of factors associated with clinical outcome across dabrafenib and trametinib combination therapy phase 3 randomized trials. Eur J Cancer. 2017;82:45\u201355. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2017.05.033\n\n.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2207_CR16","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391. \nhttps:\/\/doi.org\/10.1016\/S0895-4356(97)00049-8\n\n.","journal-title":"J Clin Epidemiol"},{"issue":"10151","key":"2207_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392(10151):971\u201384. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(18)31559-9\n\n.","journal-title":"Lancet"},{"issue":"11","key":"2207_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"17","author":"Z Karoulia","year":"2017","unstructured":"Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer. 2017;17(11):676\u201391. \nhttps:\/\/doi.org\/10.1038\/nrc.2017.79\n\n.","journal-title":"Nat Rev Cancer"},{"issue":"7287","key":"2207_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431\u20135. \nhttps:\/\/doi.org\/10.1038\/nature08833\n\n.","journal-title":"Nature"},{"issue":"1","key":"2207_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-016-0369-8","volume":"10","author":"A Daud","year":"2017","unstructured":"Daud A, Gill J, Kamra S, Chen L, Ahuja A. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017;10(1):3. \nhttps:\/\/doi.org\/10.1186\/s13045-016-0369-8\n\n.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"2207_CR21","doi-asserted-by":"publisher","first-page":"9081","DOI":"10.2147\/OTT.S171693.eCollection","volume":"2018","author":"J Sun","year":"2018","unstructured":"Sun J, Zager JS, Eroglu Z. Encorafenib\/binimetinib for the treatment of BRAF mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. Onco Target Ther. 2018;2018(11):9081\u20139. \nhttps:\/\/doi.org\/10.2147\/OTT.S171693.eCollection\n\n.","journal-title":"Onco Target Ther"},{"issue":"2","key":"2207_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/CCO.0000000000000426","volume":"30","author":"P Koelblinger","year":"2018","unstructured":"Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curre Opin Oncol. 2018;30(2):125\u201333. \nhttps:\/\/doi.org\/10.1097\/CCO.0000000000000426\n\n.","journal-title":"Curre Opin Oncol"},{"issue":"18","key":"2207_CR23","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","volume":"23","author":"JP Delord","year":"2017","unstructured":"Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, et al. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res. 2017;23(18):5339\u2013488. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2923\n\n.","journal-title":"Clin Cancer Res"},{"issue":"7287","key":"2207_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427\u201330. \nhttps:\/\/doi.org\/10.1038\/nature08902\n\n.","journal-title":"Nature"},{"issue":"7","key":"2207_CR25","doi-asserted-by":"publisher","first-page":"e67583","DOI":"10.1371\/journal.pone.0067583","volume":"8","author":"AJ King","year":"2013","unstructured":"King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions. PLoS ONE. 2013;8(7):e67583. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0067583\n\n.","journal-title":"PLoS ONE"},{"issue":"21","key":"2207_CR26","doi-asserted-by":"publisher","first-page":"30453","DOI":"10.18632\/oncotarget.8351","volume":"7","author":"CH Adelmann","year":"2016","unstructured":"Adelmann CH, Ching G, Du L, Saporito RC, Bansal V, Pence LJ, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016;7(21):30453\u201360. \nhttps:\/\/doi.org\/10.18632\/oncotarget.8351\n\n.","journal-title":"Oncotarget"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02207-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02207-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02207-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T02:29:30Z","timestamp":1600914570000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02207-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2207"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02207-7","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"assertion":[{"value":"29 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declares that they have no Conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}}]}}